Mindfully.org
Home | Air | Energy | Farm | Food | Genetic Engineering | Health | Industry | Nuclear | Pesticides | Plastic
Political | Sustainability | Technology | Water



Globalization, Inc.

Concentration in Corporate Power:
The Unmentioned Agenda
RAFI Communique i.71 Jul/Aug01

Issue: Concentration in corporate power is the defining feature of today's global economy. The "life sciences" industry is converging into new corporate structures that have profound implications for every aspect of commercial food, agriculture, and health.

Impact: Corporate hegemony is overwhelming governments and subverting national sovereignty. When governments become subservient to corporations instead of citizens, democracy is undermined, diversity is destroyed, and human rights are jeopardized. The trend in corporate consolidation is mirrored by growing disparities between rich and poor, both within and between OECD nations and the South.

Players: This issue of the ETC Communiqué provides a brief, sector-by-sector analysis of the leading companies involved in the closely related fields of pharmaceuticals, biotechnology, genomics, seeds, agrochemicals, food & beverage processing, and mega-grocery retailers.

Policy: Heads of State convening at the World Food Summit Five Years Later, 5-9 November, cannot address world food security without addressing the impact of corporate hegemony. The creation of a new United Nations Centre on Commerce and Technology, with an expanded mandate to monitor and analyze multi- technology and multi-sectoral mergers and alliances, is long overdue. The "unfinished agenda" for sustainable food security that the International Food Policy Research Institute will present in Bonn, 4-6 September, fails to include the "unmentioned agenda:" ownership, control and consolidation with respect to food security.

Top 10 Pharmaceutical Companies
                                Pharma Sales                        % Share of 
                                (US) Millions    Pharma Profit      World 
   Company                      1999/2000        Margin - 2000      Market

1. Glaxo + Smith Kline Beecham  $22,209.5        Glaxo ­ 30.9%      7.0 SKB ­ 25.1% 
2. Pfizer                       $20,500          N/A                6.5 
3. Merck & Co                   $17,481.6        26.4%              5.5 
   (includes Warner Lambert)
4. AstraZeneca                  $14,834          18.3%              4.7 
5. Aventis                      $14,808.5 pro    17.6%              4.7 
                                          forma 
6. Bristol-Myers Squibb         $14,309          28.1%              4.5 
7. Novartis                     $12,697.7        28.5%              4.0 
8. Pharmacia                    $11,177          19.6%              3.5 
  (includes Monsanto & Upjohn) 
9. Hoffman-La Roche             $10,973.8        44.2%              3.5 
10. Johnson & Johnson           $10,694          33.6%              3.4 

Source: ETC Group; based on data provided by Scrip's Pharmaceutical League Table, 2000
Global Ranking by Sector based on 2000 sales: 

                                agrochemicals, seeds & pharma       
GENE GIANT              Agrochemical   Seed            Pharmaceutical 
                        Revenues       Revenues        Revenues 
                        Ranking        Ranking         Ranking 
Syngenta                1              3               4 AstraZeneca 
                                                       7 Novartis 
Pharmacia               2              2               8 
(Monsanto)  
  Aventis               3             10               5 
                        for sale 
    BASF                4             Not ranked       Sold pharma business 
                                                       for $6.9 billion 
Dupont                  5             1 
(Pioneer)                                              Sold pharma business 
                                                       for $7.8 billion 8/01 
    Bayer               6             Not ranked       18 ­ for sale 
    Dow                 7             7                Not Ranked  

                        2000 Sales (US $million): agrochemicals, seeds & pharma 
GENE GIANT              Agrochem      Seed             Pharmaceutical 
                        Revenues      Revenues         Revenues

Syngenta                $6,100        $958 pro forma   AstraZeneca $14,834 
                                                       Novartis $12,698 
Pharmacia               $4,100        $1,600           $11,177 
(Monsanto) 
  Aventis               $3,400          $267           $14,809 pro forma 
    BASF                $3,400           N/A           Sold Pharma activities 
                                                       for $6,900 million 
Dupont                  $2,500        $1,938           $1,630 
(Pioneer)                                              Sold pharma business in 2001 
    Bayer               $2,100           N/A           $5,330 
    Dow                 $2,100          $350           N/A 

Source: ETC Group 

Top 10 Seed Companies 
                                        2000 Seed 
                                        Sales 
                                        (US) 
                                        Millions

1.  DuPont (Pioneer) USA                $1,938 
2.  Pharmacia (Monsanto) USA            $1,600 
3.  Syngenta (Switzerland) pro forma      $958 
4.  Groupe Limagrain (France)             $622 
5.  Grupo Pulsar (Seminis) Mexico         $474 
6.  Advanta (AstraZeneca and Cosun)       $373 
    UK and Netherlands 
7.  Dow (+ Cargill North America)         $350 
    USA estimate 
8.  KWS AG (Germany)                      $332 
9.  Delta & Pine Land (USA)               $301 
10. Aventis (France)                     $267 

   Source: ETC Group

Top 10 Agrochemical Companies 
                              Agchem
                              Sales
                              (US)        Share of
                              Millions,   World
    Company                   2000        Market

1.  Syngenta (Novartis +      $6,100      20% 
    AstraZeneca) pro forma 
2.  Pharmacia (Monsanto)      $4,100      14% 
3.  Aventis (AgrEvo +Rhone    $3,400      11% 
    Poulenc) 
4.  BASF (+ Cyanamid)         $3,400      11% 
    pro forma 
5.  DuPont                    $2,500       8% 
6.  Bayer                     $2,100       7% 
7.  Dow AgroSciences          $2,100       7% 
8.  Makhteshim-Agan             $675       2% 
9.  Sumitomo                    $625       2% 
10. FMC                        $575       2% 

Source: ETC Group, based on data provided by Allan

Top 10 Food & Beverage Corporations 2001 

                             Food &           F&B as 
                             Beverage         % of 
                             Sales 2000       total sales 
Company                      US$ millions     2000

Nestlé (Switzerland)         48,855           100% 
Philip Morris 
(Kraft + Nabisco)(USA)       30,907            49% 
ConAgra Inc. (+ Intl.        25,386           100% 
Home Foods) (USA) 
Unilever ( + Bestfoods)      21,127            48% 
(Netherlands/UK) 
Coca-Cola Company            20,458           100% 
(USA) 
PepsiCo Inc. (USA)           20,438           100% 
IBP Inc. (USA)               16,950           100% 
Diageo (UK)                  16,651           100% 
Mars Inc. (USA)              15,300              ? 
Groupe Danone (France)       12,308           100%

Source: ETC Group, based on Prepared Foods, July, 2001 and Fortune Global 2000. 

74% of Agbio Patents Held by Six Gene Giants

              Patents    Market
               Held      Share
Other                     26%
Pharmacia       287       21%
(Monsanto)
DuPont          279       20%
Syngenta        173       13%
Dow             157       11%
Aventis          77        6%
Grupo Pulsar     38        3%

Source: RAFI analysis of patents, 9feb01

For full text go to RAFI
The Action Group on Erosion, Technology and Concentration, formerly RAFI, is an international civil society organization headquartered in Canada. The ETC Group (pronounced Etcetera Group) is dedicated to the advancement of cultural and ecological diversity and human rights. Our new web site, www.etcgroup.org is under construction. All RAFI and ETC Group's publications are available at: www.rafi.org

If you have come to this page from an outside location click here to get back to mindfully.org